Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review.
about
Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosaInsights into Newer Antimicrobial Agents Against Gram-negative BacteriaCarbapenem resistance: overview of the problem and future perspectivesMolecular Mechanisms and Clinical Impact of Acquired and Intrinsic Fosfomycin ResistanceTreatment Options for Carbapenem-Resistant Enterobacteriaceae InfectionsClinical management of infections caused by multidrug-resistant EnterobacteriaceaeAntimicrobial Susceptibility and Molecular Mechanisms of Fosfomycin Resistance in Clinical Escherichia coli Isolates in Mainland ChinaFosfomycin susceptibility among multidrug-resistant, extended-spectrum beta-lactamase-producing, carbapenem-resistant uropathogens.Antimicrobial susceptibility of Gram-negative nonurinary bacteria to fosfomycin and other antimicrobials.Retrospective analysis of fosfomycin combinational therapy for sepsis caused by carbapenem-resistant Klebsiella pneumoniae.A Study of 24 Patients with Colistin-Resistant Gram-negative Isolates in a Tertiary Care Hospital in South India.Prevalence of fosfomycin resistance among CTX-M-producing Escherichia coli clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymesRapid detection of extended-spectrum-β-lactamase-producing enterobacteriaceae from urine samples by use of the ESBL NDP test.Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art.Bacterial prostatitis.Antimicrobial activity and clinical effectiveness of sisomicin: an evaluation of the literature (1995-2011).F33: A-: B-, IncHI2/ST3, and IncI1/ST71 plasmids drive the dissemination of fosA3 and bla CTX-M-55/-14/-65 in Escherichia coli from chickens in China.First report of a clinical, multidrug-resistant Enterobacteriaceae isolate coharboring fosfomycin resistance gene fosA3 and carbapenemase gene blaKPC-2 on the same transposon, Tn1721.Increasing antimicrobial resistance among uropathogens: Is fosfomycin the answer?Extended-spectrum-beta-lactamase producing bacteria related urinary tract infection in renal transplant recipients and effect on allograft functionDetermination of MIC distribution of arbekacin, cefminox, fosfomycin, biapenem and other antibiotics against gram-negative clinical isolates in South India: a prospective study.Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial.How to treat VAP due to MDR pathogens in ICU patients.Characterization of Fosfomycin Resistant Extended-Spectrum β-Lactamase-Producing Escherichia coli Isolates from Human and Pig in TaiwanChanges in soil bacterial communities and diversity in response to long-term silver exposure.Dissemination of the fosfomycin resistance gene fosA3 with CTX-M β-lactamase genes and rmtB carried on IncFII plasmids among Escherichia coli isolates from pets in China.New Delhi Metallo-beta lactamase-1 containing enterobacteriaceae: origin, diagnosis, treatment and public health concern.Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance.Fosfomycin tromethamine. Antibiotic of choice in the female patient: A multicenter study.Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database.Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms.The use of prophylactic single-dose fosfomycin in patients who undergo transrectal ultrasound-guided prostate biopsy: A prospective, randomized, and controlled clinical study.Fosfomycin: An Alternative Therapy for the Treatment of UTI Amidst Escalating Antimicrobial Resistance.Long-Term Fosfomycin-Tromethamine Oral Therapy for Difficult-To-Treat Chronic Bacterial Prostatitis.Validation of Cefazolin as Initial Antibiotic for First Upper Urinary Tract Infection in Children.FosfomycinUncomplicated Urinary Tract Infections and Antibiotic Resistance-Epidemiological and Mechanistic AspectsMolecular Characterization of Escherichia coli Strains Isolated from Retail Meat That Harbor blaCTX-M and fosA3 GenesMultidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.Fosfomycin: Resurgence of an old companion.
P2860
Q24612271-3E857E3C-F9D1-4B38-B7AA-C84047A5EEC7Q26751255-221C1403-8D2B-4903-AC1C-FEDF89449DB3Q26767081-91EF053E-C4C9-49EC-AF28-5DEE30372BB9Q26853135-09F654D9-2FE0-46DE-BB7D-8BEF1DC93E62Q28082546-11BBC419-F87F-400F-9442-0CC3EC84253DQ28246841-4C0A1F2E-E483-438C-830D-0BA68234CFB6Q28547100-3B22139F-B025-4477-B935-5050AA08BCD5Q33578586-A9EEDD25-5D4F-4741-BA84-966BA3D155D1Q33593516-0CC9521C-9E9E-4D13-9AA1-DFFE315FF1D7Q33597689-039584FD-5918-4F86-9E83-D4FDACC3449FQ33755535-93DAC756-DA75-4319-AC2F-C42D7D42D63AQ33962732-FF6DB6F1-DD37-4683-B02D-6578C2314D3FQ34298270-69CD3D55-2062-42B7-8684-C475507E2058Q34327857-46F2D322-F3CD-4E98-A435-2F08B96C7846Q34334684-F5A2F54D-3F45-4D49-8544-CB017EAE993DQ34650225-C4527D62-ED48-4881-9618-31F393294F2DQ34709726-7BA8C2FC-7B0A-4CE9-B9C9-64A99A6CD1BDQ34922505-3CAA986D-A931-44DE-82D7-DF2B3A32A38BQ35025362-4E6843C9-6933-4663-8F03-F5B235E8256CQ35122946-4CD0D2A0-3CD0-4D27-BE31-9BA1F3C54C7FQ35214110-B381A7EB-8C06-4342-A48E-8D259410664DQ35278325-DE7310D9-1781-4F3A-A6DF-C0E49777A337Q35457068-7D0DF550-E137-48AD-BAB2-88FD93C15839Q35747796-B38DF5F8-C5A8-490D-9481-C598431A95DDQ35782428-2598DC39-D67C-4CBC-AC86-60B4813C5FCEQ35867426-02A47C8C-370B-4615-83C6-5701B0E47565Q35885377-121D71DF-94E2-432A-A7C6-87783C685807Q35960788-68C54F99-5FA3-4B9A-BC44-53F04E008DFCQ36276787-1C107A88-371A-4C14-A5C8-899A1375EA19Q36363257-1507D5C8-3163-4575-BDCD-0D310BACD44DQ36364199-E058A161-4B82-47CC-8710-38485F420386Q36449942-49B45ED7-7444-4B8A-ADD0-63C9EDB6F475Q36476574-C1A488DF-B050-4672-B387-525EB2DE2081Q36644918-0446812E-7B8B-4EA6-9D85-67590E07ABE7Q36668671-D0E45E6B-1D12-4263-86F2-9EABDA55FFBBQ36675246-E30E607C-F20B-4CF7-9171-EC0818E55232Q36683661-CD0E08F1-E652-4D67-B6BA-EAC67C3AA26DQ36730140-FD0E63E6-CE47-415D-86ED-86B17D1F86EBQ36761826-DC98FFD6-CB76-4687-8A85-57A649F38913Q36803694-25DFFBB7-E5C0-431B-AFF6-1D92B3FFBFDA
P2860
Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Fosfomycin for the treatment o ...... fections: a systematic review.
@ast
Fosfomycin for the treatment o ...... fections: a systematic review.
@en
Fosfomycin for the treatment o ...... fections: a systematic review.
@nl
type
label
Fosfomycin for the treatment o ...... fections: a systematic review.
@ast
Fosfomycin for the treatment o ...... fections: a systematic review.
@en
Fosfomycin for the treatment o ...... fections: a systematic review.
@nl
prefLabel
Fosfomycin for the treatment o ...... fections: a systematic review.
@ast
Fosfomycin for the treatment o ...... fections: a systematic review.
@en
Fosfomycin for the treatment o ...... fections: a systematic review.
@nl
P1476
Fosfomycin for the treatment o ...... nfections: a systematic review
@en
P2093
Anastasios M Kapaskelis
Antonia C Kastoris
P356
10.1016/S1473-3099(09)70325-1
P577
2010-01-01T00:00:00Z